Nutrition
Volume 25, Issue 5 , Pages 520-525 , May 2009

A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis

Received 2 October 2008 ,Accepted 11 November 2008.

References 

  1. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory disease (IBD). Clin Exp Immunol. 1995;102:448–455
  2. Schultsz C, Van Den Berg FM, Ten Kate FW, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999;117:1089–1097
  3. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut. 2001;48:132–135
  4. Sadlack B, Merz H, Schorle H. Ulcerative colitis–like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253–261
  5. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Sueiro JL, et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–2364
  6. Hartley MG, Hudson MJ, Swarbrick ET, Hill MJ, Gent AE, Hellier MD, et al. The rectal mucosa associated microflora in patients with ulcerative colitis. J Med Microbiol. 1992;36:96–103
  7. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000;15:61–68
  8. Macfarlane S, furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis. 2004;38:1690–1699
  9. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–1633
  10. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853–858
  11. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–639
  12. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103–1108
  13. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56–63
  14. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623
  15. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–309
  16. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology. 2003;124:1202–1209
  17. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242–249
  18. Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22:1199–1204
  19. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810
  20. Hashimoto H, Green J, Iwao Y, Sakurai T, Hibi T, Fukuhara S. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. J Gastroenterol. 2003;38:1138–1143
  21. Watanabe K, Funayama Y, Fukushima K, Shibata C, Takahashi K, Ogawa H, et al. Assessment of the Japanese inflammatory bowel disease questionnaire in patients after ileal pouch anal anastomosis for ulcerative colitis. J Gastroenterol. 2006;41:662–667
  22. Tumbull GK, Vallis TM. Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. Am J Gastroenterol. 1995;90:1450–1454
  23. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol. 2001;96:1807–1815
  24. Hauser W, Dietz N, Steder-Neukamm U, Janke KH, Stallmach A. Biopsychosocial determinants of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2004;10:399–407
  25. Zahn A, Hinz U, Karner M, Ehehalt R, Stremmel W. Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:1058–1067
  26. Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:383–389
  27. Trevisi P, De Filippi S, Minieri L, Mazzoni M, Modesto M, Biavati B, et al. Effect of fructo-oligosaccharides and different doses of Bifidobacterium animalis in a weaning diet on bacterial translocation and Toll-like receptor gene expression in pigs. Nutrition. 2008;24:1023–1029
  28. Moorthy G, Murali MR, Devaraj SN. Lactbacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats. Nutrition. 2009;25:350–358
  29. Fujiwara M, Kaneko T, Iwana H, Taketomo N, Tsunoo H, Kanno J, et al. Inhibitory effects of Bifidobacterium longum on experimental ulcerative colitis induced in mice by synthetic dextran sulfate sodium. Digestion. 2003;67:90–95
  30. Bai AP, Ouyang Q, Xiao XR, Li SF. Probiotics modulate inflammatory cytokine selection from inflamed mucosa in active ulcerative colitis. Int J Clin Pract. 2006;60:284–288
  31. Takahashi N, Kitazawa H, Iwabuchi N, Xiao JZ, Miyaji K, Iwatsuki K, et al. Oral administration of an immunostimulatory DNA sequence from Bifidobacterium longum improves Th1/Th2 balance in a murine model. Biosci Biotechnol Biochem. 2006;70:2013–2017
  32. Sameshima Y, Sameshima T, Hirakawa A, Niwa K, Nagata Y, Sameshima K, et al. Effects of chitosan oral hard capsules containing Bifidobacterium longum on ulcerative colitis. J Anal Biosci. 2005;28:420–427
  33. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol. 1991;26:747–750
  34. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis (Spanish Group for the study of Crohn's Disease and Ulcerative Colitis (GETECCU)). Am J Gastroenterol. 1999;94:427–433
  35. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Balish E, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996;98:945–953
  36. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol. 1996;31:132–148
  37. Wenzl HH, Fine KD, Schiller LR, Fordtran JS. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology. 1995;108:1729–1738
  38. Eherer AJ, Santa Ana CA, Porter J, Fordtran JS. Effect of psyllium, calcium polycarbophil, and wheat bran on secretory diarrhea induced by phenolphthalein. Gastroenterology. 1993;104:1007–1012
  39. Bliss DZ, Jung HJ, Savik K, Lowry A, LeMoine M, Jensen L, et al. Supplementation with dietary fiber improves fecal incontinence. Nurs Res. 2001;50:203–213

PII: S0899-9007(08)00491-7

doi: 10.1016/j.nut.2008.11.017

Nutrition
Volume 25, Issue 5 , Pages 520-525 , May 2009

Article Tools

* Image Usage & Resolution